Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (4.6), the stock would be worth $5.14 (24% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.7 | $4.13 |
0%
|
| 3-Year Average | 4.6 | $5.14 |
+24%
|
| 5-Year Average | 4.8 | $5.33 |
+29%
|
| Industry Average | 3.1 | $3.47 |
-16%
|
| Country Average | 2.5 | $2.79 |
-32%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
O
|
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
|
235.5m USD | 3.7 | -4.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 9.4 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3.1 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.6 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 2.2 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 3.7 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 4.7 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 2.2 | 19 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 28.6 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 1.7 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.1 | 21.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Orchestra Biomed Holdings Inc
Glance View
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
